Pratyush Datta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pratyush Datta has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jayati Chakraborty
Department of Pathology, ESI-PGIMSR, Medical College Hospital and ODC (EZ), Kolkata, India
10 shared publications - Aharna Guin
Institute of Postgraduate Medical Education and Research, SSKM Hospital, Kolkata.
9 shared publications - Dia Roy
Bose Institute
9 shared publications - Diptendra Kumar Sarkar
Department of General Surgery, Institute of Post Graduate Medical Education and Research (IPGMER), Kolkata, West Bengal, India
9 shared publications - Gaurisankar Sa
Bose Institute
9 shared publications - Saikat Dutta
Division of Molecular Medicine, Bose Institute, P-1/12, Calcutta Improvement Trust Scheme VII M, Kolkata 700054, India
9 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.
- 27 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 11 (3) , 364-380
Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.
- 27 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 11 (3) , 364-380
Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.
- Open Access
- 20 February 2020
- Published by Siddharth Health Research and Social Welfare Society in Tropical Journal of Pathology and Microbiology
- Vol. 6 (2) , 146-154
A comparative study of conventional cytology and cell block method with immunohistochemistry in the diagnosis of serous effusions
Introduction: Conventional smear (CS) examination of serous effusions is of paramount importance for diagnosis, staging, prognostication, and management of malignancy. The method has some disadvantages which can be overcome by cell block (CB) preparation. CB technique increases the diagnostic accuracy due to increased cellularity, preservation of tissue architecture and feasibility of performing immunohistochemistry (IHC). Aims and Objectives: To assess and compare the diagnostic yields of CS and CB techniques for detection of malignancy in pleural and peritoneal effusions and to study the utility of CB preparation with special emphasis on the feasibility of performing IHC in identifying the primary site of malignancy in the cases of carcinoma of unknown primary (CUP). Materials and Methods: In ESI-PGIMSR, Manicktala, each of 104 fluid samples were divided into two equal parts: one part was subjected to CS technique, the smears were stained with Leishman-Giemsa and Papanicolaou stains while the other part was subjected to Plasma thromboplastin CB technique and the sections stained by Hematoxylin and Eosin. IHC was performed whenever required. Provisional diagnoses made on CSs were compared with the diagnoses revised after examining CB slides. Results: Out of 104 fluid samples, on CS, 19 (18.27%) cases were positive for malignancy, whereas on CB 39(37.5%) cases were diagnosed as malignancy. The additional yield of malignancy was 19.23% more by the CB method. IHC done on CBs could suggest the possible primary site in 31 cases. Conclusions: The current study reports the diagnostic efficiency of the CB method to be superior to that of conventional smear alone as it has various advantages. Hence CB preparation should be routinely incorporated along with the use of IHC, if required, in the evaluation of serous effusions for a more accurate diagnosis.
- 20 February 2020
- Published by Siddharth Health Research and Social Welfare Society in Tropical Journal of Pathology and Microbiology
- Vol. 6 (2) , 146-154
Open AccessA comparative study of conventional cytology and cell block method with immunohistochemistry in the diagnosis of serous effusions
Introduction: Conventional smear (CS) examination of serous effusions is of paramount importance for diagnosis, staging, prognostication, and management of malignancy. The method has some disadvantages which can be overcome by cell block (CB) preparation. CB technique increases the diagnostic accuracy due to increased cellularity, preservation of tissue architecture and feasibility of performing immunohistochemistry (IHC). Aims and Objectives: To assess and compare the diagnostic yields of CS and CB techniques for detection of malignancy in pleural and peritoneal effusions and to study the utility of CB preparation with special emphasis on the feasibility of performing IHC in identifying the primary site of malignancy in the cases of carcinoma of unknown primary (CUP). Materials and Methods: In ESI-PGIMSR, Manicktala, each of 104 fluid samples were divided into two equal parts: one part was subjected to CS technique, the smears were stained with Leishman-Giemsa and Papanicolaou stains while the other part was subjected to Plasma thromboplastin CB technique and the sections stained by Hematoxylin and Eosin. IHC was performed whenever required. Provisional diagnoses made on CSs were compared with the diagnoses revised after examining CB slides. Results: Out of 104 fluid samples, on CS, 19 (18.27%) cases were positive for malignancy, whereas on CB 39(37.5%) cases were diagnosed as malignancy. The additional yield of malignancy was 19.23% more by the CB method. IHC done on CBs could suggest the possible primary site in 31 cases. Conclusions: The current study reports the diagnostic efficiency of the CB method to be superior to that of conventional smear alone as it has various advantages. Hence CB preparation should be routinely incorporated along with the use of IHC, if required, in the evaluation of serous effusions for a more accurate diagnosis.